PEG-MGF

PEG-MGF is a chemically modified version of the MGF (Mechano Growth Factor) E-domain peptide — the C-terminal Ec E-peptide derived from the IGF-1Ec splice variant of IGF-1 — to which a polyethylene glycol (PEG) chain has been covalently attached. Native MGF is cleared within minutes, so the intended rationale for PEGylation is pharmacokinetic: the PEG moiety increases hydrodynamic size, slowing enzymatic degradation and renal filtration to extend circulating half-life. The presumed biological target is the same as unmodified MGF — activation of muscle satellite (stem) cells with increased proliferation and delayed differentiation, reportedly through a pathway distinct from the classical IGF-1 receptor. It is essential to distinguish PEG-MGF from MGF (the non-PEGylated splice-variant peptide) and from IGF-1 itself; nearly all published biology describes the unmodified E-peptide, not the pegylated form.

There is essentially no peer-reviewed evidence for the PEGylated form specifically; the underlying biology comes from studies of MGF/the IGF-1Ec E-domain peptide. Yang and Goldspink (FEBS Lett, 2002) characterised the E-peptide's distinct action on myoblasts, and Peña et al. (Biomaterials, 2015) showed that localised, sustained delivery of the MGF E-domain peptide via polymeric microstructures improved cardiac function after myocardial infarction in mice — a controlled-release approach conceptually adjacent to PEGylation, but not the same molecule. No human clinical trials of PEG-MGF exist, and it is not an approved drug. Claims of muscle-building efficacy in humans are unsupported by controlled data.

Educational overview only — no dosing instructions in the public hub.

Human safety is unknown; there are no controlled human trials. As an IGF-1-family growth-factor peptide, theoretical concerns include unregulated cell proliferation and possible promotion of pre-existing tumours. PEGylation itself adds specific uncertainties: PEG can accumulate in tissues with repeated exposure, and anti-PEG antibodies have been described. In practice, sourcing and purity dominate the risk profile, since the identity and degree of PEGylation of gray-market material cannot be verified by an end user. As a growth factor, PEG-MGF is prohibited in sport at all times.

No pharmaceutical-grade PEG-MGF exists. Any research material should carry a recent third-party Certificate of Analysis covering identity, purity (HPLC), quantification, and mass spectrometry; PEGylation also makes accurate mass characterisation and peptide-content quantification harder, so a bare 'purity' figure is insufficient. Content here reflects the peptide as described in preclinical literature on MGF, not gray-market material of unverified composition.

Research-use-only; not approved by the FDA, EMA, or other major regulators for human use. Supplying it for human consumption is unlawful in most jurisdictions. As a growth factor it falls under WADA class S2 and is prohibited in sport at all times, in and out of competition.